Raquel Bratos

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker, Matthew H. Taylor, Carol Aghajanian et al. · Journal of Clinical Oncology · 2020 · 522 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 201 citations

Medicine, Oncology, Pharmacology +16

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

David M. O’Malley, Ursula A. Matulonis, Michael J. Birrer et al. · Gynecologic Oncology · 2020 · 143 citations

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

Vicky Makker, Carol Aghajanian, Allen Lee Cohn et al. · Journal of Clinical Oncology · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacotherapy +14